MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

CRISPR Therapeutics AG

Atidarymo kaina

SektoriusSveikatos priežiūra

38.45 -0.95

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

37.92

Max

39.09

Pagrindiniai rodikliai

By Trading Economics

Pajamos

49M

-37M

Pardavimai

34M

35M

Pelnas, tenkantis vienai akcijai

-0.44

Pelno marža

-106.603

Darbuotojai

393

EBITDA

46M

-60M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+83.81% upside

Dividendai

By Dow Jones

Kitas uždarbis

2025-05-06

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

3.3B

Ankstesnė atidarymo kaina

39.4

Ankstesnė uždarymo kaina

38.45

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

CRISPR Therapeutics AG Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2024-09-26 16:08; UTC

Uždarbis
Įsigijimai, susijungimai, perėmimai

Pfizer's Strategy Looks Shakier After Sickle-Cell Disappointment -- Barrons.com

2024-09-26 14:20; UTC

Įsigijimai, susijungimai, perėmimai

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

Akcijų palyginimas

Kainos pokytis

CRISPR Therapeutics AG Prognozė

Kainos tikslas

By TipRanks

83.81% į viršų

12 mėnesių prognozė

Vidutinis 71.89 USD  83.81%

Aukščiausias 120 USD

Žemiausias 32 USD

Remiantis 19 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CRISPR Therapeutics AG kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

19 ratings

12

Pirkti

6

Laikyti

1

Parduoti

Techninis įvertinimas

By Trading Central

38.5 / 39.27Palaikymas ir pasipriešinimas

Trumpalaikis periodas

Weak Bullish Evidence

Vidutinės trukmės periodas

Strong Bearish Evidence

Ilgalaikis periodas

Bearish Evidence

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę CRISPR Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.